Skip to main content
Premium Trial:

Request an Annual Quote

NCI and Merck Sign with Aurora for Its Technology

Premium

SAN DIEGO--Aurora Biosciences announced a two-year collaboration in which it will allow the US National Cancer Institute use of its proprietary GenomeScreen technology to locate rare or low abundance transcripts in tumor cells. These transcripts often cause problems for traditional gene capture methods, and are obstacles to completing the sequencing of the entire human genome.

The company's work will support the institute's Cancer Genome Anatomy Project, a research initiative to build an index of the thousands of genes involved in human tumor development. Aurora will concentrate on genes that could be passed over by other less precise gene identification techniques in order to ensure the completeness of the tumor gene index.

Separately, Merck has exercised an option to purchase additional voltage ion probe reader systems from Aurora for ion channel drug discovery. This option was included in the collaborative research and license agreement signed by the companies in December 1997.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.